Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

Core Insights - Evotec SE has received a payment of US$ 25 million from Bristol Myers Squibb to support the progression of their joint programs focused on neurodegenerative diseases [1] Company Developments - The payment is intended to advance further research within the strategic neuroscience partnership between Evotec and Bristol Myers Squibb [1] - The collaboration aims to enhance the joint pipeline of programs targeting neurodegenerative diseases [1]